COVID-19; Long COVID; Oncology; Quality of life; SARS-CoV-2; Humans
Abstract :
[en] [en] INTRODUCTION: Long COVID is defined as the continuation of symptoms, unexplainable by alternative diagnosis, longer than four weeks after SARS-CoV-2 infection. These symptoms might hinder daily activities and overall well-being, ultimately impacting quality of life (QoL). Several studies have reported fatigue as the most common symptom, followed by dyspnoea, headache and myalgia. Although it is assumed that long COVID affects 10-20% of SARS-CoV-2 infected individuals, recently numbers up to 60% were described for patients with cancer. This study uncovers the impact of the COVID-19 pandemic on QoL of patients with cancer and how long COVID manifests in this cohort.
METHODS: A group of 96 patients with cancer was followed from March 2022 till March 2023. Online questionnaires assessing symptoms associated with long COVID, anxiety and depression (HADS), quality of life (EORTC-QLQ-C30) and cognitive functioning (CFQ) were sent every three months during this period. Furthermore, a semi-structured focus group was organised for qualitative data collection.
RESULTS: Overall, these patients reported a negative impact of the enforced COVID-19 restrictions on the emotional and psychological wellbeing. Forty nine patients with cancer (51.0%) were infected with SARS-CoV-2 over the course of the study, of which 39 (79.6%) reported long COVID symptoms. The most commonly reported symptoms were myalgia (46.2%), fatigue (38.5%) and disturbed sleep (35.9%) and it was observed that male sex is associated with poor long COVID outcomes.
CONCLUSION: While patients with cancer experience similar long COVID symptoms as healthy controls, the prevalence is remarkably higher possibly due to their compromised immune system and weakened physiological reserve.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Debie, Yana ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Santé publique vétérinaire ; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium
Palte, Ziyad; Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium
Salman, Haya; Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium
Verbruggen, Lise; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium
Vanhoutte, Greetje; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium
Chhajlani, Siddharth; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium
Raats, Silke; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium
Roelant, Ella; Clinical Trial Center (CTC), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium
Vandamme, Timon; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium
Peeters, Marc; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium
van Dam, Peter A ; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, Edegem, 2650, Belgium. Peter.vandam@uza.be ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, Wilrijk, 2610, Belgium. Peter.vandam@uza.be
Language :
English
Title :
Long-term effects of the COVID-19 pandemic for patients with cancer.
Publication date :
October 2024
Journal title :
Quality of Life Research
ISSN :
0962-9343
eISSN :
1573-2649
Publisher :
Springer Science and Business Media Deutschland GmbH, Netherlands
F. Wu et al. A new coronavirus associated with human respiratory disease in China Nature 2020 579 7798 265 269 1:CAS:528:DC%2BB3cXksFKlsLc%3D 10.1038/s41586-020-2008-3 32015508 7094943
Hosseinzadeh, P. (2022). Social consequences of the COVID-19 pandemic. A systematic review. Invest Educ Enferm, 40(1).
Lenz, C. (2023). Long-term effects of COVID-19: A review of current perspectives and mechanistic insights. Critical Reviews in Microbiology,: p. 1–14.
P. van Dam et al. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests European Journal of Cancer 2021 148 328 339 10.1016/j.ejca.2021.02.024 33773276 7914028
M. Peeters et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment ESMO Open 2021 6 5 100274 1:STN:280:DC%2BB2cnltFSqtg%3D%3D 10.1016/j.esmoop.2021.100274 34597941 8423808
S. Dubey et al. Psychosocial impact of COVID-19 Diabetes Metab Syndr 2020 14 5 779 788 10.1016/j.dsx.2020.05.035 32526627 7255207
R. Verma H.M. Kilgour K.R. Haase The Psychosocial Impact of COVID-19 on older adults with Cancer: A Rapid Review Current Oncology (Toronto, Ont.) 2022 29 2 589 601 10.3390/curroncol29020053 35200553
A.L. Pedrosa et al. Emotional, behavioral, and psychological impact of the COVID-19 pandemic Frontiers in Psychology 2020 11 566212 10.3389/fpsyg.2020.566212 33117234 7561666
A.N. Poudel et al. Impact of Covid-19 on health-related quality of life of patients: A structured review PLoS One 2021 16 10 e0259164 1:CAS:528:DC%2BB3MXitl2lsr%2FE 10.1371/journal.pone.0259164 34710173 8553121
C.M. Said F. Batchelor G. Duque The impact of the COVID-19 pandemic on physical activity, function, and Quality of Life Clinics in Geriatric Medicine 2022 38 3 519 531 10.1016/j.cger.2022.04.003 35868670 9023337
K.A. Baffert et al. Quality of life of patients with Cancer during the COVID-19 pandemic Vivo 2021 35 1 663 670 10.21873/invivo.12306
Y. Wang et al. Anxiety and depression among tibetan inpatients with cancer: A multicenter investigation Ann Palliat Med 2020 9 6 3776 3784 10.21037/apm-20-1721 33222453
Dagher, H. (2023). Long COVID in cancer patients: Preponderance of symptoms in majority of patients over long time period. Elife, 12.
O. Fankuchen et al. Long COVID in Cancer: A matched cohort study of 1-year Mortality and Long COVID Prevalence among patients with Cancer who survived an initial severe SARS-CoV-2 infection American Journal of Clinical Oncology 2023 46 7 300 305 1:CAS:528:DC%2BB3sXht1Kmsb7P 10.1097/COC.0000000000001005 37072891 10280943
M.J. Monroy-Iglesias et al. Long-term effects of COVID-19 on cancer patients: The experience from Guy’s Cancer Centre Future Oncology 2022 18 32 3585 3594 1:CAS:528:DC%2BB38Xjt1Wju7zP 10.2217/fon-2022-0088 36172860
M. Kamal et al. Assessment and characterisation of post-COVID-19 manifestations International Journal of Clinical Practice 2021 75 3 e13746 1:CAS:528:DC%2BB3MXlvVCiu78%3D 10.1111/ijcp.13746 32991035
C.E. Hastie et al. True prevalence of long-COVID in a nationwide, population cohort study Nature Communications 2023 14 1 7892 1:CAS:528:DC%2BB3sXisFSls7rP 10.1038/s41467-023-43661-w 38036541 10689486
G. Saini R. Aneja Cancer as a prospective sequela of long COVID-19 Bioessays 2021 43 6 e2000331 10.1002/bies.202000331 33914346
C.C. Lai et al. Long COVID: An inevitable sequela of SARS-CoV-2 infection Journal of Microbiology, Immunology, and Infection 2023 56 1 1 9 10.1016/j.jmii.2022.10.003 36283919
Q. Healey et al. Symptoms and signs of long COVID: A rapid review and meta-analysis J Glob Health 2022 12 05014 10.7189/jogh.12.05014 35596571 9125197
H.E. Davis et al. Long COVID: Major findings, mechanisms and recommendations Nature Reviews Microbiology 2023 21 3 133 146 1:CAS:528:DC%2BB3sXhtV2rtrw%3D 10.1038/s41579-022-00846-2 36639608 9839201
M. Marshall The lasting misery of coronavirus long-haulers Nature 2020 585 7825 339 341 1:CAS:528:DC%2BB3cXhvVOru73F 10.1038/d41586-020-02598-6 32929257
H.E. Davis et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact EClinicalMedicine 2021 38 101019 10.1016/j.eclinm.2021.101019 34308300 8280690
Y. Debie et al. Humoral and Cellular Immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in patients with Cancer Clinical Cancer Research 2023 29 3 635 646 1:CAS:528:DC%2BB3sXlt1Kmtb4%3D 10.1158/1078-0432.CCR-22-2185 36341493
Y. Debie et al. Boosting capacity of a fourth dose BNT162b2 in cancer patients European Journal of Cancer 2023 179 121 123 1:CAS:528:DC%2BB38XjtFWgsb%2FL 10.1016/j.ejca.2022.11.016 36521333
Debie, Y. (2021). Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in Cancer patients. European Journal of Cancer.
van Dam, P. A. (2022). Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients. ESMO Open,: p. 100414.
P. Fayers et al. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer European Journal of Cancer 2002 38 Suppl 4 S125 S133 10.1016/S0959-8049(01)00448-8 11858978
D.E. Broadbent et al. The cognitive failures questionnaire (CFQ) and its correlates British Journal of Clinical Psychology 1982 21 1 1 16 1:STN:280:DyaL3s%2FitlOqsw%3D%3D 10.1111/j.2044-8260.1982.tb01421.x 7126941
Caunt, J. Derbyshire Post Covid Syndrome Questionnaire. Derbyshire Post Covid Syndrome Questionnaire 2020 [cited 2023 24 April].
Burns, G. Newcastle post-COVID syndrome Follow Up Screening Questionnaire. Newcastle post-COVID syndrome Follow Up Screening Questionnaire 2020 [cited 2023 24 April].
H. Turunen M.L. Perälä P. Meriläinen [Modification of Colaizzi’s phenomenological method; a study concerning quality care] Hoitotiede 1994 6 1 8 15 1:STN:280:DyaK2czjtFanug%3D%3D 8054217
D.J. Pinato et al. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: Evidence from the OnCovid retrospective, multicentre registry study The Lancet Oncology 2021 22 12 1669 1680 1:CAS:528:DC%2BB3MXisVGksrfE 10.1016/S1470-2045(21)00573-8 34741822 8565932
J.K. Logue et al. Sequelae in adults at 6 months after COVID-19 infection JAMA Netw Open 2021 4 2 e210830 10.1001/jamanetworkopen.2021.0830 33606031 7896197
A. Subramanian et al. Symptoms and risk factors for long COVID in non-hospitalized adults Nature Medicine 2022 28 8 1706 1714 1:CAS:528:DC%2BB38XhvFGgtr%2FF 10.1038/s41591-022-01909-w 35879616 9388369
C. Huang et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study Lancet 2023 401 10393 e21 e33 10.1016/S0140-6736(23)00810-3 37321233 10258565
Magasi, S. (2022). Cancer Survivors’ Disability Experiences and Identities: A Qualitative Exploration to Advance Cancer Equity. International Journal of Environmental Research and Public Health, 19(5).
H. Crook et al. Long covid-mechanisms, risk factors, and management Bmj 2021 374 n1648 10.1136/bmj.n1648 34312178
H. Götze et al. Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis Supportive Care in Cancer 2020 28 1 211 220 10.1007/s00520-019-04805-1 31001695
W. Linden et al. Anxiety and depression after cancer diagnosis: Prevalence rates by cancer type, gender, and age Journal of Affective Disorders 2012 141 2–3 343 351 10.1016/j.jad.2012.03.025 22727334
M. Ciążyńska et al. Quality of life of cancer patients during coronavirus disease (COVID-19) pandemic Psychooncology 2020 29 9 1377 1379 10.1002/pon.5434 32779778 7323427
S.S. Jeppesen et al. Quality of life in patients with cancer during the COVID-19 pandemic - a Danish cross-sectional study (COPICADS) Acta Oncologica 2021 60 1 4 12 1:CAS:528:DC%2BB3cXitVGns77N 10.1080/0284186X.2020.1830169 33031010
F.P. Esper et al. Alpha to Omicron: Disease Severity and Clinical outcomes of Major SARS-CoV-2 variants Journal of Infectious Diseases 2023 227 3 344 352 1:CAS:528:DC%2BB3sXhsVKrtL7L 10.1093/infdis/jiac411 36214810
A. Hernandez-Aceituno A. Garcia-Hernandez E. Larumbe-Zabala COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants Infect Dis Now 2023 53 5 104688 10.1016/j.idnow.2023.104688 36858287 9970656
M.S. Durstenfeld et al. Factors Associated with Long COVID symptoms in an online cohort study Open Forum Infect Dis 2023 10 2 ofad047 10.1093/ofid/ofad047 36846611 9945931
A. Cortellini et al. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: Results from the OnCovid registry The Lancet Oncology 2023 24 4 335 346 10.1016/S1470-2045(23)00056-6 36898391 9991062
O. Byambasuren et al. Effect of covid-19 vaccination on long covid: Systematic review BMJ Med 2023 2 1 e000385 10.1136/bmjmed-2022-000385 36936268 9978692
K.I. Notarte et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review EClinicalMedicine 2022 53 101624 10.1016/j.eclinm.2022.101624 36051247 9417563
